News
DGNOF
0.146
NaN%
--
Diagnos targets June 10 Health Canada submission for next-generation CARA AI platform
PUBT · 06/05 14:12
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
Barchart · 06/05 09:00
Diagnos CEO Larente to present at Emerging Growth Conference
PUBT · 06/03 14:00
Diagnos extends maturity on CAD 300,000 convertible debentures to May 2027
PUBT · 05/13 23:00
DIAGNOS ANNOUNCES AMENDMENT TO CONVERTIBLE DEBENTURES
Reuters · 05/13 23:00
Diagnos targets Health Canada submission for new CARA in May, FDA filing by Q3-end
Reuters · 04/08 16:20
DIAGNOS INC - REMAINS ENGAGED IN SAUDI FOOD AND DRUG AUTHORITY REVIEW PROCESS FOR CARA
Reuters · 04/08 16:14
Diagnos completes annual US FDA medical device facility registration renewal
Reuters · 04/01 16:02
Diagnos extends expiry of 5.23 million warrants to Sept. 25, 2026
Reuters · 04/01 15:50
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
Barchart · 04/01 10:50
Diagnos Extends Expiry of 8,333,333 Stock Warrants to Sept. 5, 2026
Reuters · 03/05 21:06
Diagnos Extends Convertible Debenture Maturity to March 2027 and Cuts Conversion Price to $0.32
Reuters · 03/05 20:45
DIAGNOS ANNOUNCES AMENDMENTS TO CONVERTIBLE DEBENTURES AND STOCK WARRANTS
Reuters · 03/05 20:45
Diagnos posts 9M net loss of CAD 3.4 million
Reuters · 02/25 17:50
Diagnos Inc. Publishes MD&A for Three-Month and Nine-Month Periods Ended Dec. 31, 2025
Reuters · 02/25 17:49
Diagnos Inc. to Present at Centurion One Capital Toronto Growth Conference
Reuters · 02/24 14:23
Diagnos Inc. Secures Over $1 Million Federal Grant for Retinal AI Development
Reuters · 02/04 14:30
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
Barchart · 02/04 08:30
DIAGNOS Announces the Engagement of IBN
Barchart · 01/15 14:30
Diagnos Submits CARA AI Platform for Regulatory Review in Saudi Arabia
Reuters · 01/13 14:00
More
Webull provides a variety of real-time DGNOF stock news. You can receive the latest news about Diagnos Inc through multiple platforms. This information may help you make smarter investment decisions.
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.